Publications Peer reviewed articles (5) Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models Author(s): Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago-Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam , Tomer-Meir Salame, Moshit Lindzen, Yosef Yarden Published in: EMBO Molecular Medicine, 2021, ISSN 1757-4684 Publisher: Chichester Wiley Europe DOI: 10.15252/emmm.202013144 AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer Author(s): Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer Will, Soma Ghosh, Arturo Simoni-Nieves, Aakanksha Verma, Rishita Chatterjee, Simone Borgoni, Welles Robinson, Sanju Sinha, Alexander Brandis, D. Lucas Kerr, Wei Wu, Arunachalam Sekar, Suvendu Giri, Youngmin Chung, Diana Drago-Garcia, Brian P. Danysh, Matt Published in: Cancer Discovery, 2022, Page(s) 2666–2683, ISSN 2159-8290 Publisher: American Association for Cancer Research DOI: 10.1158/2159-8290.cd-22-0111 A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways Author(s): D. Romaniello, L. Mazzeo, M. Mancini, I. Marrocco, A. Noronha, M. Kreitman, S. Srivastava, S. Ghosh, M. Lindzen, T.M. Salame, A. Onn, J. Barr, Y. Yarden Published in: Clinical Cancer Research, Issue November 15, 2018, 2018, Page(s) 5610-5621, ISSN 1557-3265 Publisher: AACR DOI: 10.1158/1078-0432.ccr-18-0450 An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors Author(s): Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden Published in: EMBO Molecular Medicine, Issue 10/2, 2018, Page(s) 294-308, ISSN 1757-4676 Publisher: John Wiley & Sons Ltd. DOI: 10.15252/emmm.201708076 Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor Author(s): Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden Published in: Cancers, Issue 12/9, 2020, Page(s) 2394, ISSN 2072-6694 Publisher: Multidisciplinary Digital Publishing Institute (MDPI) DOI: 10.3390/cancers12092394 Non-peer reviewed articles (2) Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors Author(s): Yuya Haga , Ilaria Marrocco , Ashish Noronha , Mary Luz Uribe , Nishanth Belugali Nataraj , Arunachalam Sekar , Diana Drago-Garcia, Simone Borgoni, Moshit Lindzen , Suvendu Giri , Stefan Wiemann , Yasuo Tsutsumi , Yosef Yarden Published in: CANCER RESEARCH, 2021, ISSN 0008-5472 Publisher: American Association for Cancer Research DOI: 10.1158/0008-5472.can-20-3555 PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR Author(s): Soma Ghosh, Nishanth Bulugali Nataraj, Ashish Noronha, Sushant Patkar, Arunachalam Sekar, Saptaparna Mukherjee, Sabina, Winograd-Katz, Lior Kramarski, Aakanksha Verma, Moshit Lindzen, Diana Drago Garcia, Joseph Green, Galit Eisenberg, Hava Gil-Henn, Arkaprabha Basu, Yan Lender, Shimon Weiss. Moshe oren. Yosef Yarden Published in: Cell Reports, 2021, ISSN 2211-1247 Publisher: Cell Press DOI: 10.1016/j.celrep.2021.109181 Searching for OpenAIRE data... There was an error trying to search data from OpenAIRE No results available
